Corbus Pharmaceuticals
CRBP
107 hedge funds and large institutions have $51.1M invested in Corbus Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 21 increasing their positions, 42 reducing their positions, and 35 closing their positions.
78% more call options, than puts
Call options by funds: $1.39M | Put options by funds: $776K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.74% less ownership
Funds ownership: 2.3% → 1.56% (-0.74%)
12% less funds holding
Funds holding: 122 → 107 (-15)
40% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 35
50% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 42
50% less capital invested
Capital invested by funds: $103M → $51.1M (-$51.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$5.55M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$1.46M |
| 3 |
HF
HRT Financial
New York
|
+$981K |
| 4 |
JP Morgan Chase
New York
|
+$284K |
| 5 |
Squarepoint
New York
|
+$275K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$19M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.66M |
| 3 |
SG Americas Securities
New York
|
-$1.4M |
| 4 |
Rafferty Asset Management
New York
|
-$1.12M |
| 5 |
GAI
General American Investors
New York
|
-$1.08M |
CRBP Hedge Fund Activity: Q4 2020 in Review
107 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2020, worth a combined $51.1M — down 50% from $103M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of CRBP and 21 opened new positions — a net loss of 14 holders — while 42 trimmed existing stakes and 21 added.
The largest buyer was ETF Managers Group, adding an estimated $5.55M. The largest seller was State Street, cutting an estimated $19M.
- 107 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2020, down from 122 in Q3 2020.
- Funds reported $51.1M of Corbus Pharmaceuticals stock for Q4 2020, down 50% quarter-over-quarter.
- 21 funds opened new Corbus Pharmaceuticals positions in Q4 2020 and 35 closed out, a net change of -14 holders.
- The largest Corbus Pharmaceuticals buyer in Q4 2020 was ETF Managers Group, an estimated $5.55M added.
- The largest Corbus Pharmaceuticals seller in Q4 2020 was State Street, an estimated $19M sold.
Based on aggregated 13F filings for Q4 2020.